Kalaris Therapeutics earnings were -$38.7M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest KLRS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$10.2M, down 44.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, KLRS reported annual earnings of -$58.8M, with -69.1% growth.
Kalaris Therapeutics Earnings Reports & History FAQ
What were Kalaris Therapeutics's earnings last quarter?
Kalaris Therapeutics (NASDAQ: KLRS) reported Q1 2025 earnings per share (EPS) of -$2.52, up 3.08% year over year. Total KLRS earnings for the quarter were -$10.20 million. In the same quarter last year, Kalaris Therapeutics's earnings per share (EPS) was -$2.60.
Is Kalaris Therapeutics profitable or losing money?
As of the last Kalaris Therapeutics earnings report, Kalaris Therapeutics is currently losing money. Kalaris Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$38.67 million, a 74.67% decrease year over year.
What was KLRS's earnings growth in the past year?
As of Kalaris Therapeutics's earnings date in Q2 2025, Kalaris Therapeutics's earnings has grown year over year. KLRS earnings in the past year totalled -$38.67 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.